Physician profile
Alicja E Rafalowski
NPI 1447345673
$366.33
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $61.40 · 2022: $16.84.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $80.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.84 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $51.58 | 2019-2020 | |
| Pfizer INC. | $33.88 | 2019 | |
| Novo Nordisk INC | $33.84 | 2019 | |
| Amgen INC. | $20.10 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.39 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.84 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.43 | 2019 | |
| Glaxosmithkline, LLC. | $14.48 | 2019 | |
| Abbott Laboratories | $11.23 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicja Rafalowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.